Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Meir Stampfer.
Connection Strength

1.723
  1. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 1997 Mar; 6(3):189-92.
    View in: PubMed
    Score: 0.180
  2. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int J Cancer. 2009 Sep 01; 125(5):1143-6.
    View in: PubMed
    Score: 0.107
  3. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009 Aug 01; 27(22):3577-83.
    View in: PubMed
    Score: 0.106
  4. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer. 2008 Nov 18; 99(10):1743-7.
    View in: PubMed
    Score: 0.100
  5. PTEN polymorphism (IVS4) is not associated with risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2001 Apr; 10(4):411-2.
    View in: PubMed
    Score: 0.060
  6. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res. 1999 Dec 01; 59(23):5878-81.
    View in: PubMed
    Score: 0.054
  7. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.054
  8. CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians. Prostate. 1999 May; 39(2):130-4.
    View in: PubMed
    Score: 0.052
  9. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology. 1999 Jan; 53(1):121-5.
    View in: PubMed
    Score: 0.051
  10. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1998 Dec; 7(12):1075-8.
    View in: PubMed
    Score: 0.051
  11. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 1998 May; 7(5):379-84.
    View in: PubMed
    Score: 0.049
  12. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3320-3.
    View in: PubMed
    Score: 0.045
  13. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct; 13(10):1431-40.
    View in: PubMed
    Score: 0.040
  14. GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set Analysis. Clin Genitourin Cancer. 2015 Aug; 13(4):370-377.e1.
    View in: PubMed
    Score: 0.039
  15. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.037
  16. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.037
  17. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.036
  18. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
    View in: PubMed
    Score: 0.034
  19. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.033
  20. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011 Sep 12; 171(16):1487-93.
    View in: PubMed
    Score: 0.031
  21. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.030
  22. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.030
  23. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011 Jan; 107(1):126-34.
    View in: PubMed
    Score: 0.029
  24. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.029
  25. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.029
  26. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila). 2010 May; 3(5):604-10.
    View in: PubMed
    Score: 0.028
  27. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.028
  28. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics. 2010 Mar 16; 3:8.
    View in: PubMed
    Score: 0.028
  29. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
    View in: PubMed
    Score: 0.026
  30. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.026
  31. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate. 2008 Sep 15; 68(13):1416-20.
    View in: PubMed
    Score: 0.025
  32. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1682-8.
    View in: PubMed
    Score: 0.025
  33. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008 Jun 04; 100(11):815-25.
    View in: PubMed
    Score: 0.025
  34. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):249-51.
    View in: PubMed
    Score: 0.024
  35. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2233-6.
    View in: PubMed
    Score: 0.024
  36. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1557-61.
    View in: PubMed
    Score: 0.020
  37. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005 May; 14(5):1262-9.
    View in: PubMed
    Score: 0.020
  38. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res. 2005 Mar 15; 65(6):2498-504.
    View in: PubMed
    Score: 0.020
  39. Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):172-3.
    View in: PubMed
    Score: 0.017
  40. ATAAA repeat upstream of glutathione S-transferase P1 and prostate cancer risk. Urology. 2002 Jan; 59(1):159-64.
    View in: PubMed
    Score: 0.016
  41. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2001 Jul; 10(7):743-8.
    View in: PubMed
    Score: 0.015
  42. No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev. 2000 Nov; 9(11):1267-8.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.